iShares Nasdaq Biotechnology Index Fund ETF News

Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late

Smart Beta ETF report for IBB

Biotech earnings have come in upbeat in the third quarter.

Sector ETF report for IBB

Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.

Bryn Talkington, Requisite Capital, joins 'Closing Bell: Overtime' to discuss the biotech sector.

These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market i

The market has turned for the worst in recent weeks and continues to fall in a bear market fashion.  Most of our portfolio strategies are holding more than 50% cash, some are utilizing inverse ETFs,

IBB ETF has rarely been this oversold. Volume, AUM growth and reducing short interest all point to higher prices in the IBB fund.

I've written before about how biotech is the biggest technology trend of our kids' generation. Naturally, that means many people are looking for the best biotech stocks to buy.

Some major—and almost totally ignored—news from Washington, D.C., is about to upend the biotech world.

Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami an

President Joe Biden on Monday signed an executive order that aims to boost the U.S. biotechnology industry, with the move coming as he gives a speech in Boston on a “cancer moonshot.”

Smart Beta ETF report for IBB

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.